vs
Paylocity Holding Corp（PCTY）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Paylocity Holding Corp的1.6倍（$622.0M vs $387.0M），Royalty Pharma plc净利率更高（34.4% vs 13.0%，领先21.5%），Paylocity Holding Corp同比增速更快（11.3% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 2.7%）
Paylocity Holding Corp是美国领先的云端人力资源管理服务商，核心产品覆盖薪资核算、支出管理及人力资本管理（HCM）类SaaS软件，可帮助不同规模的企业客户优化人力与财务相关运营流程，有效提升管理效率、降低运营成本。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
PCTY vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.6倍
$387.0M
营收增速更快
PCTY
高出6.5%
4.8%
净利率更高
RPRX
高出21.5%
13.0%
两年增速更快
RPRX
近两年复合增速
2.7%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $387.0M | $622.0M |
| 净利润 | $50.2M | $214.2M |
| 毛利率 | 72.9% | — |
| 营业利润率 | 18.2% | 62.4% |
| 净利率 | 13.0% | 34.4% |
| 营收同比 | 11.3% | 4.8% |
| 净利润同比 | 34.0% | 2.9% |
| 每股收益（稀释后） | $0.92 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCTYRPRX
| Q4 25 | $387.0M | $622.0M | ||
| Q3 25 | $378.9M | $609.3M | ||
| Q2 25 | $369.9M | $578.7M | ||
| Q1 25 | $421.1M | $568.2M | ||
| Q4 24 | $347.7M | $593.6M | ||
| Q3 24 | $333.1M | $564.7M | ||
| Q2 24 | $324.7M | $537.3M | ||
| Q1 24 | $366.8M | $568.0M |
净利润PCTYRPRX
| Q4 25 | $50.2M | $214.2M | ||
| Q3 25 | $48.0M | $288.2M | ||
| Q2 25 | $48.6M | $30.2M | ||
| Q1 25 | $91.5M | $238.3M | ||
| Q4 24 | $37.5M | $208.2M | ||
| Q3 24 | $49.6M | $544.0M | ||
| Q2 24 | $48.8M | $102.0M | ||
| Q1 24 | $85.3M | $4.8M |
毛利率PCTYRPRX
| Q4 25 | 72.9% | — | ||
| Q3 25 | 73.9% | — | ||
| Q2 25 | 73.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 72.6% | — | ||
| Q3 24 | 74.4% | — | ||
| Q2 24 | 74.0% | — | ||
| Q1 24 | 77.8% | — |
营业利润率PCTYRPRX
| Q4 25 | 18.2% | 62.4% | ||
| Q3 25 | 19.6% | 70.1% | ||
| Q2 25 | 17.9% | 36.3% | ||
| Q1 25 | 30.2% | 94.0% | ||
| Q4 24 | 13.4% | 60.9% | ||
| Q3 24 | 19.3% | — | ||
| Q2 24 | 19.4% | 50.2% | ||
| Q1 24 | 29.0% | -13.0% |
净利率PCTYRPRX
| Q4 25 | 13.0% | 34.4% | ||
| Q3 25 | 12.7% | 47.3% | ||
| Q2 25 | 13.1% | 5.2% | ||
| Q1 25 | 21.7% | 41.9% | ||
| Q4 24 | 10.8% | 35.1% | ||
| Q3 24 | 14.9% | 96.3% | ||
| Q2 24 | 15.0% | 19.0% | ||
| Q1 24 | 23.3% | 0.8% |
每股收益（稀释后）PCTYRPRX
| Q4 25 | $0.92 | $0.49 | ||
| Q3 25 | $0.86 | $0.67 | ||
| Q2 25 | $0.87 | $0.07 | ||
| Q1 25 | $1.61 | $0.55 | ||
| Q4 24 | $0.66 | $0.46 | ||
| Q3 24 | $0.88 | $1.21 | ||
| Q2 24 | $0.85 | $0.23 | ||
| Q1 24 | $1.50 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $162.5M | $618.7M |
| 总债务越低越好 | $81.3M | $9.0B |
| 股东权益账面价值 | $1.1B | $9.7B |
| 总资产 | $7.0B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.07× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资PCTYRPRX
| Q4 25 | $162.5M | $618.7M | ||
| Q3 25 | $165.2M | $938.9M | ||
| Q2 25 | $398.1M | $631.9M | ||
| Q1 25 | $477.8M | $1.1B | ||
| Q4 24 | $482.4M | $929.0M | ||
| Q3 24 | $778.5M | $950.1M | ||
| Q2 24 | $401.8M | $1.8B | ||
| Q1 24 | $492.7M | $843.0M |
总债务PCTYRPRX
| Q4 25 | $81.3M | $9.0B | ||
| Q3 25 | $81.3M | $8.9B | ||
| Q2 25 | $162.5M | $8.0B | ||
| Q1 25 | $243.8M | $7.6B | ||
| Q4 24 | $325.0M | $7.6B | ||
| Q3 24 | $325.0M | $7.6B | ||
| Q2 24 | $0 | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益PCTYRPRX
| Q4 25 | $1.1B | $9.7B | ||
| Q3 25 | $1.1B | $9.6B | ||
| Q2 25 | $1.2B | $9.5B | ||
| Q1 25 | $1.2B | $9.8B | ||
| Q4 24 | $1.2B | $10.3B | ||
| Q3 24 | $1.1B | $10.3B | ||
| Q2 24 | $1.0B | $9.8B | ||
| Q1 24 | $1.1B | $9.9B |
总资产PCTYRPRX
| Q4 25 | $7.0B | $19.6B | ||
| Q3 25 | $4.2B | $19.3B | ||
| Q2 25 | $4.4B | $18.3B | ||
| Q1 25 | $5.2B | $17.6B | ||
| Q4 24 | $5.3B | $18.2B | ||
| Q3 24 | $4.0B | $18.0B | ||
| Q2 24 | $4.2B | $17.7B | ||
| Q1 24 | $5.0B | $16.1B |
负债/权益比PCTYRPRX
| Q4 25 | 0.07× | 0.92× | ||
| Q3 25 | 0.07× | 0.93× | ||
| Q2 25 | 0.13× | 0.84× | ||
| Q1 25 | 0.20× | 0.78× | ||
| Q4 24 | 0.28× | 0.74× | ||
| Q3 24 | 0.29× | 0.74× | ||
| Q2 24 | 0.00× | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $117.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $113.6M | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 0.9% | — |
| 现金转化率经营现金流/净利润 | 2.33× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $461.1M | — |
8季度趋势，按日历期对齐
经营现金流PCTYRPRX
| Q4 25 | $117.0M | $827.1M | ||
| Q3 25 | $86.5M | $702.6M | ||
| Q2 25 | $86.6M | $364.0M | ||
| Q1 25 | $186.0M | $596.1M | ||
| Q4 24 | $54.2M | $742.5M | ||
| Q3 24 | $91.5M | $703.6M | ||
| Q2 24 | $79.9M | $658.2M | ||
| Q1 24 | $167.5M | $664.6M |
自由现金流PCTYRPRX
| Q4 25 | $113.6M | — | ||
| Q3 25 | $82.7M | — | ||
| Q2 25 | $81.1M | — | ||
| Q1 25 | $183.7M | — | ||
| Q4 24 | $51.2M | — | ||
| Q3 24 | $89.1M | — | ||
| Q2 24 | $73.6M | — | ||
| Q1 24 | $162.0M | — |
自由现金流率PCTYRPRX
| Q4 25 | 29.4% | — | ||
| Q3 25 | 21.8% | — | ||
| Q2 25 | 21.9% | — | ||
| Q1 25 | 43.6% | — | ||
| Q4 24 | 14.7% | — | ||
| Q3 24 | 26.8% | — | ||
| Q2 24 | 22.7% | — | ||
| Q1 24 | 44.2% | — |
资本支出强度PCTYRPRX
| Q4 25 | 0.9% | — | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 1.5% | — |
现金转化率PCTYRPRX
| Q4 25 | 2.33× | 3.86× | ||
| Q3 25 | 1.80× | 2.44× | ||
| Q2 25 | 1.78× | 12.06× | ||
| Q1 25 | 2.03× | 2.50× | ||
| Q4 24 | 1.45× | 3.57× | ||
| Q3 24 | 1.84× | 1.29× | ||
| Q2 24 | 1.64× | 6.45× | ||
| Q1 24 | 1.96× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCTY
| Recurring Fees | $370.1M | 96% |
| Implementation Services And Other | $16.9M | 4% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
